» Articles » PMID: 7865613

Glucose Intolerance in Liver Cirrhosis: Role of Hepatic and Non-hepatic Influences

Overview
Specialty Biochemistry
Date 1994 Oct 1
PMID 7865613
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Oral glucose tolerance was tested in a heterogeneous group of 108 patients with liver cirrhosis. Data were compared with those from 181 subjects without liver disease (44% normal, 35% impaired glucose tolerance and 21% type 2 diabetes mellitus). In cirrhosis, 27% of the patients had normal, 36% had impaired glucose tolerance, and 37% were diabetic. There was no association between glucose intolerance or diabetes and the aetiology of cirrhosis, the duration of the disease, the biochemical indicators of hepatocyte damage, cholestasis and/or liver function. Only weak associations were found between the results of quantitative liver functions tests (caffeine, xylocaine, indocyanine green) and basal and post load glucose and insulin concentrations. Cirrhotics with 1st degree relatives with type 2 diabetes mellitus (n = 16) did not show an increased prevalence of diabetes. Older and/or malnourished patients were more frequently glucose intolerant. Using the plasma glucose concentration 120 minutes after glucose load as the dependent variable, multivariate regression analysis showed that 54% of its variance is associated with the following variables: basal plasma glucose (36%) and free fatty acid concentration (5%), age (3%), basal glucose oxidation rate (3%), muscle mass (3%) and plasma free glycerol at 120 minutes after glucose load (3%). By contrast, the clinical state of the patients (i.e. the CHILD-Pugh score) accounted for only 2% of the variance. We conclude that glucose tolerance is variable in cirrhosis. After manifestation of liver disease, glucose intolerance or diabetes cannot be explained by the clinical, histological or biochemical signs of liver disease.

Citing Articles

Intermittent fasting and the liver: Focus on the Ramadan model.

Emara M, Soliman H, Said E, Elbatae H, Elazab M, Elhefnawy S World J Hepatol. 2024; 16(8):1070-1083.

PMID: 39221099 PMC: 11362902. DOI: 10.4254/wjh.v16.i8.1070.


Electronic sanitary database: a new potential tool to identify occult chronic liver disease in general population.

Cagnin S, Martini A, Donato D, Angeli P, Pontisso P Intern Emerg Med. 2024; 19(3):641-647.

PMID: 38227274 PMC: 11039494. DOI: 10.1007/s11739-023-03507-1.


Liver acts as a metabolic gate for the traumatic brain injury pathology: Protective action of thyroid hormone.

Khandelwal M, Krishna G, Ying Z, Gomez-Pinilla F Biochim Biophys Acta Mol Basis Dis. 2023; 1869(6):166728.

PMID: 37137432 PMC: 10601893. DOI: 10.1016/j.bbadis.2023.166728.


Hepatogenous Diabetes - A Report from Central India.

Vasepalli P, Noor M, Thakur B J Clin Exp Hepatol. 2022; 12(2):312-318.

PMID: 35535090 PMC: 9077220. DOI: 10.1016/j.jceh.2021.08.018.


Hepatogenous Diabetes: A Primer.

Nath P, Anand A J Clin Exp Hepatol. 2021; 11(5):603-615.

PMID: 34511822 PMC: 8414327. DOI: 10.1016/j.jceh.2021.04.012.